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Summ a r y
In March 2014, the World Health Organization was notified of an outbreak of a 
communicable disease characterized by fever, severe diarrhea, vomiting, and a high 
fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as 
the causative agent. Full-length genome sequencing and phylogenetic analysis 
showed that EBOV from Guinea forms a separate clade in relationship to the known 
EBOV strains from the Democratic Republic of Congo and Gabon. Epidemiologic 
investigation linked the laboratory-confirmed cases with the presumed first fatal-
ity of the outbreak in December 2013. This study demonstrates the emergence of a 
new EBOV strain in Guinea.
Outbreaks caused by viruses of the genera ebolavirus and mar-burgvirus represent a major public health issue in sub-Saharan Africa. Ebola virus disease is associated with a case fatality rate of 30 to 90%, de-
pending on the virus species. Specific conditions in hospitals and communities in 
Africa facilitate the spread of the disease from human to human. Three ebolavirus 
species have caused large outbreaks in sub-Saharan Africa: EBOV, Sudan ebolavirus, 
and the recently described Bundibugyo ebolavirus.1,2 Epidemics have occurred in the 
Democratic Republic of Congo, Sudan, Gabon, Republic of Congo, and Uganda. 
Reston ebolavirus circulates in the Philippines. It has caused disease in nonhuman 
primates but not in humans.3 The fifth species, Tai Forest ebolavirus, was documented 
in a single human infection caused by contact with an infected chimpanzee from 
the Tai Forest in Ivory Coast.4 Although this event indicated the presence of Tai For-
est ebolavirus in West Africa, this subregion was not considered to be an area in 
which EBOV was endemic.
On March 10, 2014, hospitals and public health services in Guéckédou and 
Macenta alerted the Ministry of Health of Guinea and — 2 days later — Médecins 
sans Frontières in Guinea about clusters of a mysterious disease characterized by 
fever, severe diarrhea, vomiting, and an apparent high fatality rate. (Médecins sans 
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Frontières had been working on a malaria proj-
ect in Guéckédou since 2010.) In Guéckédou, 
eight patients were hospitalized; three of them 
died, and additional deaths were reported 
among the families of the patients. Several 
deaths were reported in Macenta, including 
deaths among hospital staff members. A team 
sent by the health ministry reached the out-
break region on March 14 (Fig. 1). Médecins 
sans Frontières in Europe was notified and sent a 
team, which arrived in Guéckédou on March 18. 
Epi demiologic investigation was initiated, and 
blood samples were collected and sent to the 
biosafety level 4 laboratories in Lyon, France, 
and Ham burg, Germany, for virologic analysis.
Me thods
Patients
Blood samples were obtained from 20 patients 
who were hospitalized in Guéckédou, Macenta, 
and Kissidougou with fever, diarrhea, vomiting, 
or hemorrhage. Demographic and clinical data 
for the patients were provided on the laboratory 
request forms. Clinical data were not collected in 
a systematic fashion. This work was performed 
as part of the public health response to contain 
the outbreak in Guinea; informed consent was 
not obtained.
Diagnostic Assays
Viral RNA was extracted from 50 to 100 μl of 
undiluted plasma and 1:10 diluted plasma with 
the use of the QIAmp viral RNA kit (Qiagen). 
Nucleic acid amplification tests for detection of 
filoviruses and arenaviruses were performed with 
the use of commercially available kits and pub-
lished primers and probes5-11 (Table S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org).
Viral Sequencing
Fragments amplified by filovirus L gene-specific 
primers were sequenced with the use of poly-
merase-chain-reaction (PCR) primers. Complete 
EBOV genomes were sequenced directly with the 
use of RNA extracted from serum obtained from 
three patients with high levels of viral RNA, as 
measured on real-time reverse-transcriptase–PCR 
(RT-PCR) analysis. The genome was amplified in 
overlapping fragments with the use of EBOV-
specific primers. The fragments were sequenced 
from both ends with the use of conventional 
Sanger techniques. The sequence of the contigs 
was verified by visual inspection of the electro-
pherograms.
Viral Isolation
About 100 μl of all serum samples was used to 
inoculate Vero E6 cells maintained in 25-cm2
flasks in Dulbecco’s Modified Eagle’s Medium 
containing 2 to 5% fetal-calf serum and penicil-
lin–streptomycin. Cells and supernatant were 
passaged several times. Virus growth in the cells 
was verified on immunofluorescence with the 
use of polyclonal mouse anti-EBOV–specific anti-
bodies in serum of mice challenged with EBOV 
or on the basis of an increase in viral levels in the 
cell-culture supernatant over several orders of 
magnitude, as measured on real-time RT-PCR.
Electron Microscopy
Specimens from two patients were prepared for 
electron microscopy with the use of a conven-
tional negative-staining procedure. In brief, a 
drop of 1:10 diluted serum was adsorbed to a 
glow-discharged carbon-coated copper grid and 
stained with freshly prepared 1% phosphotung-
stic acid (Agar Scientific). Images were taken at 
room temperature with the use of a Tecnai Spirit 
electron microscope (FEI) equipped with an LaB6 
filament and operated at an acceleration voltage 
of 80 kV.
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Figure 1. Map of Guinea Showing Initial Locations of the Outbreak of Ebola 
Virus Disease.
The area of the outbreak is highlighted in red. The main road between the 
outbreak area and Conakry, the capital of Guinea, is also shown. The map 
was modified from a United Nations map.
The New England Journal of Medicine 
Downloaded from nejm.org on April 21, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
brief report
n engl j med nejm.org 3
Phylogenetic Analysis
We obtained all 48 complete genome sequences 
of filoviruses that are currently available from 
GenBank and aligned them with the new EBOV 
Guinea sequences (18,959 nucleotides). We used 
software designed to perform statistical selec-
tion of best-fit models of nucleotide substitu-
tion (jModelTest12) to identify the general time-
reversible model of sequence evolution with 
gamma-distributed rate variation among sites 
(GTR+gamma) as the model that best describes 
the phylogenetic data. We used the Bayesian 
Markov Chain Monte Carlo method, as imple-
mented in MrBayes 3.1.2 software,13 to infer the 
composition of one phylogenetic tree, using 
two runs of four chains with 1 million steps 
with a burn-in rate of 25% and the GTR+gamma 
model. A second tree was inferred for the same 
alignment with a maximum-likelihood method 
implemented in PhyML software14 under the 
Table 1. Demographic, Clinical, and Virologic Characteristics of 15 Patients with Confirmed Ebola Virus Disease during the 2014 Outbreak  
in Guinea.*
Patient
Number Age (yr) Sex Hospital
Date of 
Sampling Symptoms Outcome
Date 
of Death
Virus  
Isolation
GenBank 
Accession 
Number
C1 20 F Guéckédou March 12 Fever, diarrhea, 
vomiting
Died March 18 No ND
C2 25 F Guéckédou March 13 Fever, diarrhea, 
vomiting
Died March 25 No ND
C3 35 M Guéckédou March 13 Fever, vomiting Died March 17 No ND
C4 25 M Guéckédou March 18 Fever, diarrhea, 
vomiting, 
hemorrhage
Died March 18 No ND
C5 16 F Guéckédou March 19 Spontaneous 
abortion
Survived — Yes KJ660348
C6 27 F Guéckédou March 20 Fever, diarrhea, 
vomiting
Died ND No ND
C7 47 F Guéckédou March 20 Fever, diarrhea, 
vomiting
Died March 22 Yes KJ660347
C8 29 M Macenta March 16 Fever, hemor-
rhage
Died March 16 No ND
C9 55 F Macenta March 16 Fever, diarrhea, 
vomiting
Died March 19 No ND
C10 17 M Macenta March 16 Fever, diarrhea, 
vomiting
ND ND No ND
C11 7  M Macenta ND Fever, diarrhea, 
vomiting
Died March 26 No ND
C12 30  M Macenta, 
Nzérékoré
February 28 Fever, vomiting Died February 28 Yes ND
C13 50  M Macenta March 12 Fever, diarrhea, 
vomiting
Died March 12 Yes ND
C14 41  M Macenta, 
Nzérékoré
March 13 Fever, diarrhea, 
vomiting, 
hemorrhage
Died March 16 No ND
C15 28 F Kissidougou March 17 Fever, diarrhea, 
vomiting, 
hemorrhage
Survived — Yes KJ660346
* All sampling and recording of patients’ status were performed in 2014. ND denotes not determined.
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Meliandou Village, Guéckédou  
9 Deaths from Dec. 2, 2013, to Feb. 8, 2014
2 Deaths on March 26, 2014
Guéckédou Baladou District
First onset Feb. 23, 2014
14 Deaths from March 1 to March 31, 2014
Guéckédou Farako District
First onset Feb. 24, 2014
4 Deaths from Feb. 28 to March 25, 2014
CI C2 C5
S14 Health care worker at Guéckédou
hospital
Fever, diarrhea, vomiting
Onset Feb. 5, 2014
Went to Macenta hospital;
died Feb. 10, 2014
First recorded cases of the outbreak
(S1) Child, 2 yr of age
Fever, black stool, vomiting
Onset Dec. 2, 2013; died Dec. 6, 2013
Dawa Village, Guéckédou
8 Deaths from Jan. 26 to March 27, 2014
Macenta
15 Deaths from Feb. 10 to March 29, 2014
Guéckédou
Gbandou Village, Guéckédou
3 Deaths from March 9 to March 12, 2014
Dandou Pombo Village, Guéckédou
6 Deaths from Feb. 11 to March 31, 2014
(S7) Sister of S4, attended funeral of S4
Fever, diarrhea, vomiting, hemorrhage
Onset Jan. 20, 2014; died Jan. 26, 2014
(S8) Attended funeral of S4
Fever, bleeding
Onset Jan. 25, 2014; died Jan. 30, 2014
(S9–S12) 
Onset Feb. 2–16, 2014; died Feb. 11–
March 5, 2014
(S2) Sister of S1, 3 yr of age
Fever, black diarrhea, vomiting
Onset Dec. 25, 2013; died Dec. 29, 2013
(S3) Mother of S1 and S2
Bleeding
Died Dec. 13, 2013
(S4) Grandmother of S1 and S2
Fever, diarrhea, vomiting
Died Jan. 1, 2014
(S5) Nurse
Fever, diarrhea, vomiting
Onset Jan. 29, 2014; died Feb. 2, 2014
(S6) Village midwife
Fever
Hospitalized in Guéckédou Jan. 25, 2014;
died Feb. 2, 2014
(S13) Family member of S6, took care of S6
Fever, hemorrhage
Onset Feb. 4, 2014; died Feb. 11, 2014
C6 C7 Mother-in-law of S14Died March 22, 2014
Family
members
of S14
(S15) Doctor at Macenta hospital; took care of S14
Vomiting, bleeding, hiccups
Onset Feb. 19, 2014; died Feb. 24, 2014
Funeral in Kissidougou 
Kissidougou
5 Deaths from March 7 to March 26, 2014
(S16) Brother of S15
Fever, vomiting
Onset Feb. 24, 2014; died March 7, 2014
(S17) Brother of S15
Fever, vomiting, hiccups
Onset Feb. 24, 2014; transferred from
Guéckédou hospital to Kissidougou;
died March 8, 2014
CI3 C12 C14
Family member of S15
and contact of S14
Died Feb. 28, 2014,
in Nzérékoré
Contact with S15 and affected
family members of S15
Onset March 3, 2014; died
March 12, 2014
2 Further deaths in family
Contact with C12 in Macenta
Hospitalized in Macenta
March 6, 2014
Died March 16, 2014,
in Nzérékoré
C8 C9
C10
C15
C11
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GTR+gamma model with 1000 bootstrap repli-
cations.
Epidemiologic Investigations
We gathered data on possible transmission chains 
from hospital records and through interviews 
with patients in whom EBOV infection was sus-
pected and their contacts, affected families, in-
habitants of villages in which deaths occurred, 
attendants of funerals, public health authorities, 
and hospital staff members.
R esult s
Identification of the EBOV Strain
To detect the causative agent, we used conven-
tional Filoviridae-specific RT-PCR assays target-
ing a conserved region in the L gene to test sam-
ples obtained from 20 hospitalized patients who 
were suspected of being infected with a hemor-
rhagic fever virus.5,6,9 In addition, we performed 
EBOV-specific real-time RT-PCR assays targeting 
the glycoprotein (GP) or nucleoprotein (NP) 
gene.7,10 Samples from 15 of 20 patients tested 
positive in the conventional L gene PCR assay and 
the real-time assays (Table 1). EBOV was identi-
fied in the serum of one patient on electron mi-
croscopy (Fig. 2, inset) and was isolated in cell 
culture from 5 patients. None of the samples 
were positive for Lassa virus on Lassa virus–spe-
cific RT-PCR assays.8,11 Sequencing of the frag-
ments amplified by the L gene RT-PCR assays 
revealed EBOV sequences. The partial L gene se-
quences were identical for all confirmed cases, 
except for a synonymous T-to-C polymorphism at 
position 13560, which was found in Patients C12 
and C14.
Sequencing of Samples from Patients
The EBOV in samples obtained from three patients 
was completely sequenced with the use of con-
ventional Sanger techniques (GenBank accession 
numbers, KJ660346, KJ660347, and KJ660348). 
The three sequences, each 18,959 nucleotides in 
length, were identical with the exception of a few 
polymorphisms at positions 2124 (G→A, synony-
mous), 2185 (A→G, NP552 glycine→glutamic acid), 
2931 (A→G, synonymous), 4340 (C→T, synony-
mous), 6909 (A→T, sGP291 arginine→tryptophan), 
and 9923 (T→C, synonymous). The Guinean EBOV 
strain showed 97% identity to EBOV strains from 
the Democratic Republic of Congo and Gabon. 
Phylogenetic analysis of the full-length sequences 
by means of Bayesian and maximum-likelihood 
methods revealed a separate, basal position of the 
Guinean EBOV within the EBOV clade (Fig. 3).
clinical and Epidemiologic Analysis
The prominent clinical features of the EBOV in-
fection in the confirmed cases were fever, severe 
diarrhea, and vomiting; hemorrhage was less fre-
quent. The case fatality rate in the initial cases 
was 86% (12 of 14 patients with a known out-
come died). Confirmed cases originated from 
hospitals in Guéckédou, Macenta, Nzérékoré, and 
Kissidougou prefectures (Fig. 1). We performed 
an epidemiologic look-back investigation of the 
transmission chains by reviewing hospital docu-
mentations and interviews with affected fami-
lies, patients with suspected disease, and inhab-
itants of villages in which cases occurred. 
According to the current state of the epidemio-
logic investigation, the suspected first case of the 
outbreak was a 2-year-old child who died in Me-
liandou in Guéckédou prefecture on December 6, 
2013 (Fig. 2). Patient S14, a health care worker 
from Guéckédou with suspected disease, seems 
to have triggered the spread of the virus to Ma-
centa, Nzérékoré, and Kissidougou in February 
2014. As the virus spread, 13 of the confirmed 
cases could be linked to four clusters: the Bala-
dou district of Guéckédou, the Farako district of 
Guéckédou, Macenta, and Kissidougou. Eventu-
ally, all clusters were linked with several deaths 
in the villages of Meliandou and Dawa between 
December 2013 and March 2014.
Current Status of the Ongoing Outbreak
This report is focused on the initial phase and geo-
graphic origin of the EBOV outbreak. Before the 
Figure 2 (facing page). Transmission Chains  
in the Outbreak of Ebola Virus Disease in Guinea.
Shown are transmission chains in the Ebola virus dis-
ease outbreak involving laboratory-confirmed cases. 
The presumed means of transmission of Zaire ebolavirus 
(EBOV), as revealed by epidemiologic investigation, 
are indicated by solid arrows. Dashed arrows indicate 
that the epidemiologic links are not well established. 
Laboratory-confirmed cases (C) are indicated with red 
circles, and suspected cases (S) are indicated with the 
case number. The inset image is an electron micro-
scopic scan of the Guinean strain of EBOV in blood 
obtained from a patient. A typical complete virus parti-
cle, with the ends marked by arrows, and two degraded 
particles (arrowheads) are shown (scale bar, 100 nm).
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end of March 2014 (week 13), a total of 111 clini-
cally suspected cases with 79 deaths (71% case 
fatality rate on the basis of clinical suspicion) had 
been recorded in the prefectures of Guéckédou, 
Macenta, and Kissidougou. Accord ing to the time-
line of the transmission chains (Fig. 2), the out-
break of confirmed disease started in the prefec-
ture Guéckédou and then spread to Macenta and 
Kissidougou (Fig. 4). The male-to-female ratio 
among patients who died was 41:59; the median 
age was 35 years (interquartile range, 25 to 51).
Discussion
This study demonstrates the emergence of EBOV 
in Guinea. The high degree of similarity among 
the 15 partial L gene sequences, along with the 
three full-length sequences and the epidemio-
logic links between the cases, suggest a single 
introduction of the virus into the human popula-
tion. This introduction seems to have happened 
in early December 2013 or even before. Further 
epidemiologic investigation is ongoing to iden-
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Figure 3. Phylogenetic Analysis of the Ebolavirus Genus, Including the EBOV Strains from Guinea.
The phylogenetic tree was inferred with the use of the Bayesian Markov Chain Monte Carlo method. A second tree 
that was inferred for the same set of sequences with a maximum-likelihood method confirmed the Bayesian tree 
(data not shown). Bayesian posterior probabilities and bootstrap percentages (1000 replicates of the maximum-
likelihood tree) are shown on the branches. For clarity of presentation, the branches for the non-EBOV species were 
shortened and condensed (dashed branches). The GenBank accession number, strain designation, country of origin, 
and year of isolation are indicated on the EBOV branches. The EBOV Guinea strain is available from the European 
Virus Archive (www.european-virus-archive.com/).
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tify the presumed animal source of the outbreak. 
It is suspected that the virus was transmitted for 
months before the outbreak became apparent 
because of clusters of cases in the hospitals of 
Guéckédou and Macenta. This length of expo-
sure appears to have allowed many transmission 
chains and thus increased the number of cases of 
Ebola virus disease.
The clinical picture of the initial cases was 
predominantly fever, vomiting, and severe diar-
rhea. Hemorrhage was not documented for most 
of the patients with confirmed disease at the 
time of sampling but may have developed during 
the later course of the disease. The term Ebola 
virus disease (rather than the earlier term Ebola 
hemorrhagic fever) takes into account that hem-
orrhage is not seen in all patients15 and may 
help clinicians and public health officials in the 
early recognition of the disease. The case fatal-
ity rate was 86% among the early confirmed 
cases and 71% among clinically suspected cases, 
which is consistent with the case fatality rates 
observed in previous EBOV outbreaks.15-17
Phylogenetic analysis of the full-length se-
quences established a separate clade for the 
Guinean EBOV strain in sister relationship with 
other known EBOV strains. This suggests that 
the EBOV strain from Guinea has evolved in 
parallel with the strains from the Democratic 
Republic of Congo and Gabon from a recent 
ancestor and has not been introduced from the 
latter countries into Guinea. Potential reservoirs 
of EBOV, fruit bats of the species Hypsignathus 
monstrosus, Epomops franqueti, and Myonycteris tor-
quata, are present in large parts of West Africa.18 
It is possible that EBOV has circulated unde-
tected in this region for some time. The emer-
gence of the virus in Guinea highlights the risk 
of EBOV outbreaks in the whole West African 
subregion.
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Figure 4. Number of Suspected Cases of Ebola Virus Disease, According to 
Prefecture and Week.
The cases in Guéckédou, Macenta, and Kissidougou prefectures were re-
corded by the local public health authorities in collaboration with the World 
Health Organization and Médecins sans Frontières.
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